174 related articles for article (PubMed ID: 22566872)
21. Immunophenotype of normal and myelomatous plasma-cell subsets.
Robillard N; Wuillème S; Moreau P; Béné MC
Front Immunol; 2014; 5():137. PubMed ID: 24744760
[TBL] [Abstract][Full Text] [Related]
22. Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?
Pozdzik A; Beukinga I; Gu-Trantien C; Willard-Gallo K; Nortier J; Pradier O
Mediators Inflamm; 2016; 2016():7651024. PubMed ID: 27493452
[TBL] [Abstract][Full Text] [Related]
23. CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis.
Nørgaard NN; Holien T; Jönsson S; Hella H; Espevik T; Sundan A; Standal T
J Immunol; 2010 Sep; 185(6):3131-9. PubMed ID: 20702733
[TBL] [Abstract][Full Text] [Related]
24. Toll-like receptor 9 ligand blocks osteoclast differentiation through induction of phosphatase.
Amcheslavsky A; Bar-Shavit Z
J Bone Miner Res; 2007 Aug; 22(8):1301-10. PubMed ID: 17488193
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF.
Abu-Rish EY; Amrani Y; Browning MJ
Rheumatology (Oxford); 2013 Jul; 52(7):1190-201. PubMed ID: 23436580
[TBL] [Abstract][Full Text] [Related]
26. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis.
Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z
J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640
[TBL] [Abstract][Full Text] [Related]
27. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.
Rivellese F; Manou-Stathopoulou S; Mauro D; Goldmann K; Pyne D; Rajakariar R; Gordon P; Schafer P; Bombardieri M; Pitzalis C; Lewis MJ
Lupus Sci Med; 2021 Mar; 8(1):. PubMed ID: 33727237
[TBL] [Abstract][Full Text] [Related]
28. Cytidine-phosphate-guanosine oligodeoxynucleotides in combination with CD40 ligand decrease periodontal inflammation and alveolar bone loss in a TLR9-independent manner.
Zhao Q; Hu Y; Deng S; Yu P; Chen B; Wang Z; Han X
J Appl Oral Sci; 2018; 26():e20170451. PubMed ID: 29791566
[TBL] [Abstract][Full Text] [Related]
29. Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in Waldenström macroglobulinemia.
Lim JH; Wang JQ; Webb F; Saxena K; Enosi Tuipulotu D; Pandey A; Man SM; Talaulikar D
iScience; 2022 Aug; 25(8):104856. PubMed ID: 35992066
[TBL] [Abstract][Full Text] [Related]
30. CD40 ligand triggers interleukin-6 mediated B cell differentiation.
Urashima M; Chauhan D; Hatziyanni M; Ogata A; Hollenbaugh D; Aruffo A; Anderson KC
Leuk Res; 1996 Jun; 20(6):507-15. PubMed ID: 8709623
[TBL] [Abstract][Full Text] [Related]
31. Cytidine-phosphate-guanosine oligonucleotides induce interleukin-8 production through activation of TLR9, MyD88, NF-κB, and ERK pathways in odontoblast cells.
He W; Zhang Y; Zhang J; Yu Q; Wang P; Wang Z; Smith AJ
J Endod; 2012 Jun; 38(6):780-5. PubMed ID: 22595112
[TBL] [Abstract][Full Text] [Related]
32. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation.
Kemp TJ; Moore JM; Griffith TS
J Immunol; 2004 Jul; 173(2):892-9. PubMed ID: 15240676
[TBL] [Abstract][Full Text] [Related]
33. Enhanced T cell-independent antibody responses in c-Jun N-terminal kinase 2 (JNK2)-deficient B cells following stimulation with CpG-1826 and anti-IgM.
Cao Y; Takada E; Hata K; Sudo K; Furuhata M; Mizuguchi J
Immunol Lett; 2010 Aug; 132(1-2):38-44. PubMed ID: 20665951
[TBL] [Abstract][Full Text] [Related]
34. A distinct Toll-like receptor repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 and CpG-2006 stimulation.
Månsson A; Adner M; Höckerfelt U; Cardell LO
Immunology; 2006 Aug; 118(4):539-48. PubMed ID: 16780564
[TBL] [Abstract][Full Text] [Related]
35. A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines.
Assaf A; Esteves H; Curnow SJ; Browning MJ
Cell Immunol; 2009; 259(1):90-9. PubMed ID: 19573862
[TBL] [Abstract][Full Text] [Related]
36. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau JL; Rapp MJ; Juge-Morineau N; Wijdenes J; Amiot M
Blood; 1994 Oct; 84(8):2597-603. PubMed ID: 7522634
[TBL] [Abstract][Full Text] [Related]
37. Cpg-ODN, a TLR9 Agonist, Aggravates Myocardial Ischemia/Reperfusion Injury by Activation of TLR9-P38 MAPK Signaling.
Xie L; He S; Kong N; Zhu Y; Tang Y; Li J; Liu Z; Liu J; Gong J
Cell Physiol Biochem; 2018; 47(4):1389-1398. PubMed ID: 29929196
[TBL] [Abstract][Full Text] [Related]
38. Plasma cells and nonplasma B cells express differing IgE repertoires in allergic sensitization.
Rogosch T; Kerzel S; Sikula L; Gentil K; Liebetruth M; Schlingmann KP; Maier RF; Zemlin M
J Immunol; 2010 May; 184(9):4947-54. PubMed ID: 20363970
[TBL] [Abstract][Full Text] [Related]
39. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
40. CD138 and CD31 Double-Positive Cells Comprise the Functional Antibody-Secreting Plasma Cell Compartment in Primate Bone Marrow.
Martinez-Murillo P; Pramanik L; Sundling C; Hultenby K; Wretenberg P; Spångberg M; Karlsson Hedestam GB
Front Immunol; 2016; 7():242. PubMed ID: 27446073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
